Form 4: Medicine Man Technologies Executive Daniel Pabon Reports Transaction in Company Stock

Sentiment:

SEC Form 4 Filing


Daniel Pabon, Chief Regulatory Officer of Medicine Man Technologies, reports a transaction involving the company's common stock on April 11, 2024.

Summary

  • On April 11, 2024, Daniel Pabon, the Chief Regulatory Officer of Medicine Man Technologies, Inc. (SHWZ), engaged in a transaction involving the company's common stock.
  • The transaction involved the disposition of 150 shares of common stock at a price of $0.7.
  • Following the reported transaction, Mr. Pabon's beneficial ownership of Medicine Man Technologies' common stock remains at 150 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure related to insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.

Stakeholder Impact

  • The transaction may have a minor impact on shareholders due to the small number of shares involved.

Key Dates

DateDescription
04/11/2024Date of stock transaction
04/15/2024Date of signature on the report

Keywords

Form 4, Beneficial Ownership, Daniel Pabon, Medicine Man Technologies, SHWZ, Stock Transaction, Chief Regulatory Officer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.